{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:27:07Z","timestamp":1791379627822,"version":"4.3.3"},"reference-count":46,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nMethadone is a long-acting opioid utilized in the management of chronic pain and opioid dependency. Given its unique pharmacokinetics and potential for both therapeutic benefit and risk, understanding prescribing patterns is essential. This study aimed to evaluate methadone utilization at a single academic university over a one-year period as well as discuss important considerations of methadone pharmacology.\nMethods\nA retrospective review was conducted using electronic medical records to assess the number of methadone prescriptions issued across the institution between January 1, 2024, and December 31, 2024. The total number of prescriptions was analyzed and categorized into four quarters. In Q1 (January\u2013March), 96 prescriptions were issued, followed by 109 in Q2 (April\u2013June), 120 in Q3 (July\u2013September), and 145 in Q4 (October\u2013December).\nResults\nA total of 470 methadone prescriptions were issued during the study period, demonstrating a steady increase over the year. The percentage increase in methadone prescriptions from Q1 to Q4 was approximately 51%. Notably, this analysis did not differentiate between prescriptions for chronic pain versus opioid dependency treatment. The rise likely reflects prescribing for pain management, as methadone for OUD is typically dispensed through regulated clinics not captured in this data. However, some prescriptions may reflect dual management by addiction medicine providers within our institution.\nConclusions\nThis study highlights a consistent rise in methadone prescriptions at this particular institution, underscoring the need for further investigation into prescribing patterns, patient demographics, and clinical indications. Future research should stratify prescriptions by primary indication to better understand the drivers of methadone utilization and its impact on patient outcomes.<\/jats:p>","DOI":"10.64719\/pb.4548","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"43-54","source":"Crossref","is-referenced-by-count":2,"title":["Methadone Prescribing Patterns at a Single Institution: A Retrospective Study and Clinical Implications"],"prefix":"10.64719","volume":"55","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amad","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328\u2013e332. doi: 10.1097\/j.pain.0000000000002291.","DOI":"10.1097\/j.pain.0000000000002291"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Dahlhamer J, Lucas J, Zelaya C et al. Prevalence of chronic pain and high-impact chronic pain among adults \u2013 United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001\u20131006. doi: 10.15585\/mmwr.mm6736a2.","DOI":"10.15585\/mmwr.mm6736a2"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019;123(2):e273\u2013e283. doi: 10.1016\/j.bja.2019.03.023. Epub 2019 May 10.","DOI":"10.1016\/j.bja.2019.03.023"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082\u20132097. doi: 10.1016\/S0140-6736(21)00393-7.","DOI":"10.1016\/S0140-6736(21)00393-7"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Thanh NX, Tanguay RL, Manhas KJP et al. Economic burden of chronic pain in Alberta, Canada. PLoS One. 2022;17(8):e0272638. doi: 10.1371\/journal.pone.0272638.","DOI":"10.1371\/journal.pone.0272638"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715\u2013724. doi: 10.1016\/j.jpain.2012.03.009. Epub 2012 May 16.","DOI":"10.1016\/j.jpain.2012.03.009"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Shi Y, Wu W. Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. BMC Med. 2023;21(1):372. doi: 10.1186\/s12916-023-03076-2.","DOI":"10.1186\/s12916-023-03076-2"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Patel R, Dickenson AH. Neuropharmacological basis for multimodal analgesia in chronic pain. Postgrad Med. 2022;134(3):245\u2013259. doi: 10.1080\/00325481.2021.1985351. Epub 2021 Oct 28.","DOI":"10.1080\/00325481.2021.1985351"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Guven Kose S, Kose HC, Celikel F et al. Chronic pain: an update of clinical practices and advances in chronic pain management. Eurasian J Med. 2022;54(Suppl1):57\u201361. doi: 10.5152\/eurasianjmed.2022.22307.","DOI":"10.5152\/eurasianjmed.2022.22307"},{"key":"ref10","unstructured":"Anekar AA, Hendrix JM, Cascella M. Treasure Island (FL): StatPearls Publishing; 2023. Apr 23, WHO analgesic ladder. In: StatPearls [Internet] 2025 Jan\u2013."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Crush J, Levy N, Knaggs RD, Lobo DN. Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong. Br J Anaesth. 2022;129(2):137\u2013142. doi: 10.1016\/j.bja.2022.03.004. Epub 2022 Apr 6.","DOI":"10.1016\/j.bja.2022.03.004"},{"key":"ref12","unstructured":"Maharty DC, Hines SC, Brown RB. Chronic low back pain in adults: evaluation and management. Am Fam Physician. 2024;109(3):233\u2013244."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Migliorini F, Maffulli N, Eschweiler J et al. The pharmacological management of chronic lower back pain. Expert Opin Pharmacother. 2021;22(1):109\u2013119. doi: 10.1080\/14656566.2020.1817384. Epub 2020 Sep 4.","DOI":"10.1080\/14656566.2020.1817384"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Cerda IH, Jung H, Guerrero MC et al. Trends in celecoxib prescribing: a single institution 16-month review. J Clin Med. 2025;14(8):2823. doi: 10.3390\/jcm14082823.","DOI":"10.3390\/jcm14082823"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother. 2010;11(17):2813\u20132825. doi: 10.1517\/14656566.2010.507192. Epub 2010 Jul 19.","DOI":"10.1517\/14656566.2010.507192"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Robinson C, Dalal S, Chitneni A et al. A look at commonly utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in chronic pain. Health Psychol Res. 2022;10(3):32309. doi: 10.52965\/001c.32309.","DOI":"10.52965\/001c.32309"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Malik A, Brown Z, Ryder A et al. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for treatment of fibromyalgia: a comprehensive clinical review. Psychopharmacol Bull. 2025;55(2):24\u201340.","DOI":"10.64719\/pb.4519"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tran RT, Patil AS, Nguyen PP et al. Prescribing patterns of gabapentinoids in chronic pain management: a single institution retrospective chart review. Psychopharmacol Bull. 2025;55(1):26\u201336.","DOI":"10.64719\/pb.4510"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014(4):CD007938. doi: 10.1002\/14651858.CD007938.pub3. Update in: Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. doi:10.1002\/14651858.CD007938.pub4.","DOI":"10.1002\/14651858.CD007938.pub3"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wiffen PJ, Derry S, Bell RF et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. doi: 10.1002\/14651858.CD007938.pub4.","DOI":"10.1002\/14651858.CD007938.pub4"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Adhikari S, Bista D, Shrestha R, Woods D. Prescribing patterns and off-label use of gabapentinoid agents at dhulikhel hospital, nepal: a cross-sectional study. J Pain Res. 2024;17:4377\u20134391. doi: 10.2147\/JPR.S493542.","DOI":"10.2147\/JPR.S493542"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chang WJ. Muscle relaxants for acute and chronic pain. Phys Med Rehabil Clin N Am. 2020;31(2):245\u2013254. doi: 10.1016\/j.pmr.2020.01.005. Epub 2020 Mar 13.","DOI":"10.1016\/j.pmr.2020.01.005"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain \u2013 United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395. doi: 10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Kaye AM, Knezevic NN et al. Comprehensive, evidence-based, consensus guidelines for prescription of opioids for chronic non-cancer pain from the American Society of Interventional Pain Physicians (ASIPP) Pain Physician. 2023;26(7S):S7\u2013S126.","DOI":"10.36076\/ppj.2023.26.S7"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Brown P, Ryder A, Robinson C, Valenti K, Phung K, Hasoon J. Methadone for chronic pain: a review of pharmacology, efficacy, and safety concerns. Health Psychol Res. 2025;13:129552. doi: 10.52965\/001c.129552.","DOI":"10.52965\/001c.129552"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ragaban F, Purohit O, Del Fabbro E. Methadone in cancer-related neuropathic pain: a narrative review. Curr Oncol. 2024;31(12):7613\u20137624. doi: 10.3390\/curroncol31120561.","DOI":"10.3390\/curroncol31120561"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Santin L, Verlato G, Tfaily A et al. Methadone maintenance and QT-interval: prevalence and risk factors-is it effective to switch therapy to levomethadone? Biomedicines. 2023;11(8):2109. doi: 10.3390\/biomedicines11082109.","DOI":"10.3390\/biomedicines11082109"},{"key":"ref28","unstructured":"Centers for Disease Control and Prevention (CDC) Vital signs: risk for overdose from methadone used for pain relief \u2013 United States, 1999\u20132010. MMWR Morb Mortal Wkly Rep. 2012;61(26):493\u2013497."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Faul M, Bohm M, Alexander C. Methadone prescribing and overdose and the association with medicaid preferred drug list policies \u2013 United States, 2007\u20132014. MMWR Morb Mortal Wkly Rep. 2017;66(12):320\u2013323. doi: 10.15585\/mmwr.mm6612a2.","DOI":"10.15585\/mmwr.mm6612a2"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone\u2014metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50(6):551\u2013559. doi: 10.1016\/j.phrs.2004.05.002.","DOI":"10.1016\/j.phrs.2004.05.002"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Koehl A, Hu H, Maeda S et al. Structure of the \u03bc-opioid receptor-Gi protein complex. Nature. 2018;558(7711):547\u2013552. doi: 10.1038\/s41586-018-0219-7. Epub 2018 Jun 13.","DOI":"10.1038\/s41586-018-0219-7"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219\u2013230. doi: 10.2165\/00003088-197601030-00004.","DOI":"10.2165\/00003088-197601030-00004"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532\u2013543. doi: 10.1111\/bph.14105. Epub 2018 Jan 6.","DOI":"10.1111\/bph.14105"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Matsuda Y, Okayama S. Oral methadone for patients with neuropathic pain due to neoplastic brachial plexopathy. J Palliat Care. 2022;37(2):77\u201382. doi: 10.1177\/08258597211016564. Epub 2021 May 11.","DOI":"10.1177\/08258597211016564"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Pu\u015fca\u015fu C, Chiri\u0163\u0103 C, Negre\u015f S, Blebea NM. Exploring the therapeutic potential of N-methyl-D-aspartate receptor antagonists in neuropathic pain management. Int J Mol Sci. 2024;25(20):11111. doi: 10.3390\/ijms252011111.","DOI":"10.3390\/ijms252011111"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011;15(2):129\u2013136. doi: 10.1007\/s11916-010-0171-1.","DOI":"10.1007\/s11916-010-0171-1"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9(6):724\u2013727. doi: 10.1111\/j.1526-4637.2008.00501.x. Erratum in: Pain Med. 2008;9(8);1228.","DOI":"10.1111\/j.1526-4637.2008.00501.x"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Peirano GP, Mammana GP, Bertolino MS et al. Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit. Support Care Cancer. 2016;24(8):3551\u20133556. doi: 10.1007\/s00520-016-3191-5. Epub 2016 Mar 29.","DOI":"10.1007\/s00520-016-3191-5"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag. 2006;2(5):269\u2013276. doi: 10.5055\/jom.2006.0040.","DOI":"10.5055\/jom.2006.0040"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Habashy C, Springer E, Hall EA, Anghelescu DL. Methadone for pain management in children with cancer. Paediatr Drugs. 2018;20(5):409\u2013416. doi: 10.1007\/s40272-018-0304-2.","DOI":"10.1007\/s40272-018-0304-2"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Rhodin A, Gr\u00f6nbladh L, Nilsson LH, Gordh T. Methadone treatment of chronic non-malignant pain and opioid dependence\u2014a long-term follow-up. Eur J Pain. 2006;10(3):271\u20138. doi: 10.1016\/j.ejpain.2005.05.003. Epub 2005 Jun 21.","DOI":"10.1016\/j.ejpain.2005.05.003"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J. 2004;80(949):654\u2013659. doi: 10.1136\/pgmj.2004.022988.","DOI":"10.1136\/pgmj.2004.022988"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Fipps DC, Oesterle TS, Kolla BP. Opioid maintenance therapy: a review of methadone, buprenorphine, and naltrexone treatments for opioid use disorder. Semin Neurol. 2024;44(4):441\u2013451. doi: 10.1055\/s-0044-1787571. Epub 2024 Jun 7.","DOI":"10.1055\/s-0044-1787571"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Nosyk B, Min JE, Homayra F et al. Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder. JAMA. 2024;332(21):1822\u20131831. doi: 10.1001\/jama.2024.16954.","DOI":"10.1001\/jama.2024.16954"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Kreutzwiser D, Tawfic QA. Methadone for pain management: a pharmacotherapeutic review. CNS Drugs. 2020;34(8):827\u2013839. doi: 10.1007\/s40263-020-00743-3.","DOI":"10.1007\/s40263-020-00743-3"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Chou R, Cruciani RA, Fiellin DA et al. American Pain Society; Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15(4):321\u2013337. doi: 10.1016\/j.jpain.2014.01.494.","DOI":"10.1016\/j.jpain.2014.01.494"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:46Z","timestamp":1791315226000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/methadone-prescribing-patterns-at-a-single-institution-a-retrospective-study-and-clinical-implications\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4548","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}